Can Clinical Predictive Models Identify Patients Who Should Not Receive TAVR? A Systematic Review
暂无分享,去创建一个
[1] G. Elwyn,et al. The Learning Curve for Shared Decision-making in Symptomatic Aortic Stenosis. , 2020, JAMA cardiology.
[2] Jinny G. Park,et al. Clinical Prediction Models for Valvular Heart Disease , 2019, Journal of the American Heart Association.
[3] Sean M. O'Brien,et al. Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease. , 2019, Journal of the American College of Cardiology.
[4] V. Falk,et al. Pulmonary Hypertension in Patients With Severe Aortic Stenosis: Prognostic Impact After Transcatheter Aortic Valve Replacement: Pulmonary Hypertension in Patients Undergoing TAVR. , 2019, JACC. Cardiovascular imaging.
[5] J. Carroll,et al. 2018 AATS/ACC/SCAI/STS Expert Consensus Systems of Care Document: Operator and Institutional Recommendations and Requirements for Transcatheter Aortic Valve Replacement: A Joint Report of the American Association for Thoracic Surgery, American College of Cardiology, Society for Cardiovascular Angiog , 2019, The Annals of thoracic surgery.
[6] J. Carroll,et al. 2018 AATS/ACC/SCAI/STS Expert Consensus Systems of Care Document: Operator and Institutional Recommendations and Requirements for Transcatheter Aortic Valve Replacement: A Joint Report of the American Association for Thoracic Surgery, American College of Cardiology, Society for Cardiovascular Angiog , 2019, Journal of the American College of Cardiology.
[7] M. Enriquez-Sarano,et al. Transcatheter Aortic Valve Replacement in Patients With Low-Flow, Low-Gradient Aortic Stenosis: The TOPAS-TAVI Registry. , 2018, Journal of the American College of Cardiology.
[8] R. Kornowski,et al. Transcatheter Aortic Valve Implantation Futility Risk Model Development and Validation Among Treated Patients With Aortic Stenosis. , 2017, The American journal of cardiology.
[9] I. Buchan,et al. Novel United Kingdom prognostic model for 30-day mortality following transcatheter aortic valve implantation , 2017, Heart.
[10] J. Kelly,et al. Assessment of Commonly Used Frailty Markers for High- and Extreme-Risk Patients Undergoing Transcatheter Aortic Valve Replacement. , 2017, The Annals of thoracic surgery.
[11] M. Mack,et al. Quality-of-Life Outcomes After Transcatheter Aortic Valve Replacement in an Unselected Population: A Report From the STS/ACC Transcatheter Valve Therapy Registry , 2017, JAMA cardiology.
[12] Gowri Raman,et al. Tufts PACE Clinical Predictive Model Registry: update 1990 through 2015 , 2017, Diagnostic and Prognostic Research.
[13] D. Adams,et al. Predicting Early and Late Mortality After Transcatheter Aortic Valve Replacement. , 2016, Journal of the American College of Cardiology.
[14] I. Barbash,et al. Mortality prediction following transcatheter aortic valve replacement: A quantitative comparison of risk scores derived from populations treated with either surgical or percutaneous aortic valve replacement. The Israeli TAVR Registry Risk Model Accuracy Assessment (IRRMA) study. , 2016, International journal of cardiology.
[15] K. Gauvreau,et al. Palliative Care for Patients With End-Stage Cardiovascular Disease and Devices: A Report From the Palliative Care Working Group of the Geriatrics Section of the American College of Cardiology. , 2016, JAMA internal medicine.
[16] Sean M. O'Brien,et al. Development and Validation of a Risk Prediction Model for In-Hospital Mortality After Transcatheter Aortic Valve Replacement. , 2016, JAMA cardiology.
[17] J. Carroll,et al. Annual Outcomes With Transcatheter Valve Therapy: From the STS/ACC TVT Registry. , 2016, The Annals of thoracic surgery.
[18] J. Carroll,et al. Annual Outcomes With Transcatheter Valve Therapy: From the STS/ACC TVT Registry. , 2015, Journal of the American College of Cardiology.
[19] F. Lin,et al. Risk stratification in patients with pulmonary hypertension undergoing transcatheter aortic valve replacement , 2015, Heart.
[20] M. Mack,et al. 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial , 2015, The Lancet.
[21] M. Mack,et al. A call for an evidence-based approach to the Heart Team for patients with severe aortic stenosis. , 2015, Journal of the American College of Cardiology.
[22] John D. Carroll,et al. Clinical outcomes at 1 year following transcatheter aortic valve replacement. , 2015, JAMA.
[23] J. Leipsic,et al. Prevalence and impact of preoperative moderate/severe tricuspid regurgitation on patients undergoing transcatheter aortic valve replacement , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[24] Jeroen J. Bax,et al. Value of the "TAVI2-SCORe" versus surgical risk scores for prediction of one year mortality in 511 patients who underwent transcatheter aortic valve implantation. , 2015, The American journal of cardiology.
[25] P. Stella,et al. Usefulness and validation of the survival posT TAVI score for survival after transcatheter aortic valve implantation for aortic stenosis. , 2014, The American journal of cardiology.
[26] K. Alexander,et al. Futility, benefit, and transcatheter aortic valve replacement. , 2014, JACC. Cardiovascular interventions.
[27] Francesco Santini,et al. A simple risk tool (the OBSERVANT score) for prediction of 30-day mortality after transcatheter aortic valve replacement. , 2014, The American journal of cardiology.
[28] M. Mack,et al. Predictors of Poor Outcomes After Transcatheter Aortic Valve Replacement: Results From the PARTNER (Placement of Aortic Transcatheter Valve) Trial , 2014, Circulation.
[29] Pascal Leprince,et al. Predictive factors of early mortality after transcatheter aortic valve implantation: individual risk assessment using a simple score , 2014, Heart.
[30] R. Erbel,et al. Comparison between different risk scoring algorithms on isolated conventional or transcatheter aortic valve replacement. , 2014, The Annals of thoracic surgery.
[31] E. Tuzcu,et al. Outcomes of patients with chronic lung disease and severe aortic stenosis treated with transcatheter versus surgical aortic valve replacement or standard therapy: insights from the PARTNER trial (placement of AoRTic TraNscathetER Valve). , 2014, Journal of the American College of Cardiology.
[32] J. Bavaria,et al. Predictors of Mortality and Outcomes of Therapy in Low-Flow Severe Aortic Stenosis: A Placement of Aortic Transcatheter Valves (PARTNER) Trial Analysis , 2013, Circulation.
[33] Andreas Beckmann,et al. German Aortic Valve Score: a new scoring system for prediction of mortality related to aortic valve procedures in adults. , 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.
[34] D. Wood,et al. Clinical ResearchInterventional CardiologyTranscatheter Aortic Valve Replacement: Outcomes of Patients With Moderate or Severe Mitral Regurgitation , 2012 .
[35] G. Nickenig,et al. Renal function as predictor of mortality in patients after percutaneous transcatheter aortic valve implantation. , 2010, JACC. Cardiovascular interventions.
[36] S. Pocock,et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. , 2010, The New England journal of medicine.
[37] T. Trikalinos,et al. The Empirical Basis for Determinations of Medical Futility , 2010, Journal of General Internal Medicine.
[38] D. Kent,et al. Competing risk and heterogeneity of treatment effect in clinical trials , 2008, Trials.
[39] R. Bansal,et al. Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. , 2006, The Annals of thoracic surgery.
[40] A. Jonsen,et al. Medical futility: its meaning and ethical implications. , 1990, Annals of internal medicine.
[41] T. Nealon. The American Association for Thoracic Surgery , 1972 .